Paper Details

  1. Home
  2. Paper Details

Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.

Author: KelmanLeslie, Von SeggernRandal L

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study compares the cost-effectiveness of six oral triptans for treating acute migraine headaches. Almotriptan 12.5 mg was found to be the most cost-effective option, providing the highest sustained pain-free rate with the lowest adverse event rate compared to other triptans.
Paper Details　
Original Abstract of the Article :
The objective of this study was to use the patient-centered efficacy measurements of sustained pain free and sustained pain free with no adverse events to compare the relative cost-effectiveness of 6 oral triptans in the treatment of acute migraine. Adverse event and sustained pain-free rates were o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/16988536

データ提供：米国国立医学図書館（NLM）

Finding the Right Triptan: Cost-Effectiveness in Migraine Treatment

Migraine headaches can be debilitating, and finding the right treatment is crucial for alleviating pain and improving quality of life. This study examines the cost-effectiveness of different triptan medications for treating acute migraine headaches. The researchers analyzed data from clinical trials to compare the efficacy and cost-effectiveness of six oral triptans, considering both pain relief and side effects. The findings suggest that almotriptan 12.5 mg emerges as the most cost-effective option, providing the best balance of efficacy and tolerability.

Almotriptan: A Cost-Effective Option for Migraine Treatment

The study found that almotriptan 12.5 mg was the most cost-effective triptan for achieving both sustained pain relief and sustained pain relief with no adverse events. This suggests that almotriptan could be a valuable treatment option for migraine sufferers seeking a balance of effectiveness and tolerability.

Navigating the World of Migraine Treatments

This research provides valuable insights for individuals struggling with migraine headaches. The findings highlight the importance of considering both efficacy and cost-effectiveness when choosing a migraine treatment. Almotriptan emerges as a potentially beneficial option for many migraine sufferers. Remember, my dear friends, just like the desert traveler seeks the most efficient route, we must seek the most effective and affordable treatment for our health concerns.

Dr.Camel's Conclusion

This study compares the cost-effectiveness of different triptan medications for treating acute migraine headaches. The findings suggest that almotriptan 12.5 mg is the most cost-effective option, providing the best balance of efficacy and tolerability. This research provides valuable insights for individuals seeking effective and affordable migraine treatment options.

Date :
  1. Date Completed 2006-10-30
  2. Date Revised 2006-11-15
Further Info :

Pubmed ID

16988536

DOI: Digital Object Identifier

00045391-200609000-00007

Related Literature

Article Analysis
・Effects of naratriptan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.